Target intelligence / Profile preview

T cell receptor beta joining 1-1 (TRBJ1-1)

Target
TRBJ1-1
Molecular classification
Other (immunoglobulin gene segment), Component of “T cell receptor beta chain” (when rearranged)
01

Overview

TRBJ1-1 (T cell receptor beta joining 1-1) is a gene segment located within the TCR beta locus. It encodes one of the joining (J) regions that are recombined during T cell development to generate the variable domain of the beta chain of the T cell receptor (TCRβ)[3][5]. This recombination, involving variable (V), diversity (D), and joining (J) gene segments, allows an individual’s immune system to generate a diverse repertoire of TCRs for antigen recognition[2][5]. The T cell receptor itself is a membrane-bound protein complex on T lymphocytes, crucial for the specific recognition of antigens presented by major histocompatibility complex (MHC) molecules[2][4][5]. The diversity of TCRs, created in part by segments such as TRBJ1-1, is vital for effective immune surveillance and response[5]. However, TRBJ1-1 is not itself a protein, receptor, or protypical therapeutic target or receptor, but one of several building blocks for the TCR complex.

Other names
TRBJ1-1TRBJ11TCRBJ1S1
02

Mechanism of action

Not applicable; TRBJ1-1 is not directly druggable.

03

Biological functions

Somatic recombination for antigen receptor diversityGeneration of complementarity-determining region 3 (CDR3) of TCRβ chainDoes not have direct signaling or effector function itself
04

Disease associations

Other (Indirect, as part of T cell receptor diversity, which influences immune responses and disease susceptibility)Altered TCR repertoires can be seen in cancer, autoimmune diseases, and infections, but not assigned to TRBJ1-1 specifically
05

Safety considerations

None, as TRBJ1-1 is not a druggable target or therapeutic agent.
06

Biomarkers

The usage pattern of specific TCR joining segments (including TRBJ1-1) may theoretically serve as a research marker of T cell clonality or immune repertoire studies, but it is not a clinically validated “biomarker” for patient selection or efficacy monitoring

Beyond the preview

Go deeper on T cell receptor beta joining 1-1 (TRBJ1-1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on T cell receptor beta joining 1-1 (TRBJ1-1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call